Nyxoah SA

NYXH Healthcare Medical Instruments & Supplies

Nyxoah SA’s revenue for fiscal 2025 (year ended December 2025) was $11.3 million, up 131.7% from fiscal 2024. In the quarter to June 2026, revenue grew 486.6%, EPS fell 6.35%, free cash flow grew 4.01% and total debt rose 185.4%, each against the same quarter a year earlier. Revenue growth for five consecutive years.

1.11 0.08 −6.72%
Market cap
$121.2M
P/E
0.0×
Fwd P/E
−1.7×
Dividend yield
—
F-score
3/9
Altman Z
−4.39
Beneish M
−2.78
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
27.99 15.46 7.14 3.84
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(8.10) (10.46) (5.00) (5.04)
P/B ratio
3.07 3.15 3.01 1.00
EV/Sales
27.62 14.79 7.77 2.06
EV/EBITDA
0.00 0.00 0.00 0.00
EV/FCF
(2.17) (2.04) (1.57) (0.60)
Current Ratio
1.70 1.25 0.99 2.38
Net Debt/EBITDA
0.09 0.35 (0.50) 2.04
Debt/Equity
0.40 0.84 0.99 0.72
Earnings Yield
(54.13%) (58.26%) (84.93%) (149.11%)
Free Cash Flow Yield
(45.41%) (46.95%) (69.22%) (89.78%)
Free Cash Flow per Share
(0.57) (0.48) (0.60) (0.37)
Book value per Share
1.50 1.46 0.97 1.69
Free Cash Flow
(21.43) (18.22) (25.73) (21.12)
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates